SCHEMBL6765220

SCHEMBL6765220

CN(CCOc1ccc(CC2NC(=O)SC2=O)cc1)c1cccc(Oc2ccc(Cl)cc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 8/20 0.46
PPARA Q07869 2/20 0.46
RARG P13631 1/20 0.41
RXRA P19793 1/20 0.41
AGER Q15109 2/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HTT P42858 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HSD17B10 Q99714 1/20 0.34
P2RX3 P56373 4/20 0.34
PKM P14618 1/20 0.33
FFAR1 O14842 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6767115 0.93 PPARG (0.49) PPARGPPARARARGRXRAMAPT
SCHEMBL1415625 0.87 PPARG (0.41) PPARGPPARARARGRXRAAGER
SCHEMBL1415411 0.81 PPARG (0.44) PPARGPPARARARGRXRA
SCHEMBL602342 0.81 PPARG (0.67) PPARGPPARARARGRXRAMAPT
SCHEMBL6606406 0.80 PPARG (0.66) PPARGPPARARARGRXRAMAPT
SCHEMBL1415555 0.79 PPARG (0.42) PPARGPPARARARGRXRA
SCHEMBL1415448 0.79 PPARG (0.49) PPARGPPARARARGRXRAALDH1A1
SCHEMBL1415361 0.79 PPARG (0.42) PPARGPPARARARGRXRASMN1; SMN2
SCHEMBL1415517 0.79 PPARG (0.42) PPARGPPARARARGRXRASMN1; SMN2
SCHEMBL1415588 0.79 PPARG (0.43) PPARGPPARARARGRXRAFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6787551-B2 ORAL ADMINISTRATION; TREATING INSULIN RESISTANCE USING A NEW MECHANISM TO LOWER BLOOD SUGAR LEVEL BY INCREASING PHYSIOLOG-ICAL EFFECTS OF INSULIN ON TARGET CELLS (MUSCLE, ADIPOCYTES, LIVER); ALSO STRONGER ANTILIPIDEMIC THAN ROSIGLITAZONE CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) 2004-09-07 US claimed